Eli Lilly Raises Annual Profit Forecast on Strength of Diabetes Drug

Reuters2023-04-27

(Reuters) - Eli Lilly and Co raised its full-year profit forecast on Thursday, betting on the approval of its diabetes drug, tirzepatide, for the treatment of obesity expected later this year.

The company said earlier on Thursday that it plans to complete its rolling submission to the U.S. Food and Drug Administration for use of tirzepatide in obesity patients in the coming weeks, following positive data from a second late-stage study.

The study showed that a high dose helped people with type 2 diabetes who were also obese or overweight to lose nearly 16% of their body weight.

Lilly now expects adjusted 2023 earnings of $8.65 to $8.85 per share, compared with its prior forecast of $8.35 to $8.55. Analysts were expecting annual profit of $8.45 per share, according to Refinitiv estimates.

Sales of the drug, sold under the brand name Mounjaro for diabetes, came in at $568.5 million, beating estimates of $422.5 million, according to an average of four analysts polled by Refinitiv.

Shares of the U.S. drugmaker rose 4.84% before the bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment